Deals roundup
Capio acquiring Medocular, Swedish eye health company
A Medical Device Daily Staff Report
Capio (Gotenburg, Sweden) has acquired 100% of the shares in Sweden-based Medocular, which specializes in general eye medicine, cataract surgery and treatment of defective-vision disorders, such as short-sightedness.
Medocular has annual sales of slightly more than $6.6 million, with 45 employees. The formal transfer of ownership will take place on Oct. 1. As part of the deal, Capio acquired all of Medoculars operations in Uppsala, Stockholm, Norrkoping, Linkoping, Gothenburg and Malmo, all in Sweden.
Medoculars operations focus primarily on assignments from the public health sector and the company annually carries out approximately 10% of all cataract operations in Sweden. Medocular will become part of Capios Healthcare Nordic business area.
Through Medocular, Capio gains a prominent position within eye health care services in Sweden and a strong platform for international expansion in this field, said Stanley Broden, director of Capios Healthcare Nordic. Rudolph Hahnenberger, president of Medocular, said, As part of the Capio Group, we see major opportunities for the further development of eye health care services in a broader context and for being able to increase availability for patients over the longer term.
In other dealmaking activities:
Exten Industries (San Diego, California) said it finalized its acquisition of all outstanding shares of MultiCell Associates (MCA; Warwick, Rhode Island), and will operate MCA as a wholly owned subsidiary. MCA owns the rights to certain patented technology for engineering human and other mammalian liver cells. These non-tumorigenic cells have applications for drug discovery and toxicological testing and could perform metabolic functions in liver-assist devices. Additionally, the cells have shown the ability to generate very complex proteins that have a variety of therapeutic and research applications. Terms were not disclosed.